Literature DB >> 14551721

Transdermal testosterone delivery: testosterone patch and gel.

Louis J G Gooren1, Mathijs C M Bunck.   

Abstract

Testosterone replacement treatment is usually life-long. Fortunately, testosterone administration is relatively safe and until the age of 50 years few side effects are noted with normal doses of testosterone. After the age of 50 years when prostate disease becomes more prevalent, shorter-acting testosterone preparations, allowing a fast reduction of circulating testosterone levels, may be an advantage. Testosterone has an impact on sexual and non-sexual behaviour and short-acting testosterone preparations may be better suited for the initiation of long-term administration allowing the monitoring of behavioural effects. Testosterone can be delivered to the circulation through the intact skin, both genital and non-genital. Transdermal administration delivers testosterone at a controlled rate into the systemic circulation, avoiding hepatic first pass and reproducing the diurnal rhythm of testosterone secretion and without the peak and trough levels observed with the use of the traditional long-acting testosterone injections. In conclusion, both the testosterone patch and testosterone gel are valuable contributions to androgen replacement treatment meeting the requirements specified for testosterone replacement treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14551721     DOI: 10.1007/s00345-003-0368-6

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  14 in total

1.  Evaluation of the pharmacokinetic profiles of the new testosterone topical gel formulation, Testim, compared to AndroGel.

Authors:  T Marbury; E Hamill; R Bachand; T Sebree; T Smith
Journal:  Biopharm Drug Dispos       Date:  2003-04       Impact factor: 1.627

2.  Use of topical corticosteroid pretreatment to reduce the incidence and severity of skin reactions associated with testosterone transdermal therapy.

Authors:  D E Wilson; K Kaidbey; S C Boike; D K Jorkasky
Journal:  Clin Ther       Date:  1998 Mar-Apr       Impact factor: 3.393

3.  Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal system.

Authors:  S Arver; A S Dobs; A W Meikle; R P Allen; S W Sanders; N A Mazer
Journal:  J Urol       Date:  1996-05       Impact factor: 7.450

4.  Interpersonal testosterone transfer after topical application of a newly developed testosterone gel preparation.

Authors:  C Rolf; U Knie; G Lemmnitz; E Nieschlag
Journal:  Clin Endocrinol (Oxf)       Date:  2002-05       Impact factor: 3.478

5.  Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men.

Authors:  R S Swerdloff; C Wang; G Cunningham; A Dobs; A Iranmanesh; A M Matsumoto; P J Snyder; T Weber; J Longstreth; N Berman
Journal:  J Clin Endocrinol Metab       Date:  2000-12       Impact factor: 5.958

6.  Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7-10 years.

Authors:  H M Behre; S von Eckardstein; S Kliesch; E Nieschlag
Journal:  Clin Endocrinol (Oxf)       Date:  1999-05       Impact factor: 3.478

7.  A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function.

Authors:  T A McNicholas; J D Dean; H Mulder; C Carnegie; N A Jones
Journal:  BJU Int       Date:  2003-01       Impact factor: 5.588

Review 8.  Transdermal dihydrotestosterone treatment of 'andropause'.

Authors:  B de Lignieres
Journal:  Ann Med       Date:  1993-06       Impact factor: 4.709

9.  AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function.

Authors:  C Steidle; S Schwartz; K Jacoby; T Sebree; T Smith; R Bachand
Journal:  J Clin Endocrinol Metab       Date:  2003-06       Impact factor: 5.958

10.  Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men.

Authors:  A W Meikle; N A Mazer; J F Moellmer; J D Stringham; K G Tolman; S W Sanders; W D Odell
Journal:  J Clin Endocrinol Metab       Date:  1992-03       Impact factor: 5.958

View more
  8 in total

Review 1.  Leydig cells: formation, function, and regulation.

Authors:  Barry R Zirkin; Vassilios Papadopoulos
Journal:  Biol Reprod       Date:  2018-07-01       Impact factor: 4.285

Review 2.  Leydig cell aging and hypogonadism.

Authors:  M C Beattie; L Adekola; V Papadopoulos; H Chen; B R Zirkin
Journal:  Exp Gerontol       Date:  2015-02-18       Impact factor: 4.032

Review 3.  The Roles of Androgens in Humans: Biology, Metabolic Regulation and Health.

Authors:  Marià Alemany
Journal:  Int J Mol Sci       Date:  2022-10-08       Impact factor: 6.208

Review 4.  Testosterone replacement therapy and prostate cancer: a word of caution.

Authors:  Timothy C Brand; Edith Canby-Hagino; Ian M Thompson
Journal:  Curr Urol Rep       Date:  2007-05       Impact factor: 3.092

5.  Comparative bioavailability of metoprolol tartrate after oral and transdermal administration in healthy male volunteers.

Authors:  M Aqil; A Ali; Y Sultana; N Saha
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

6.  Pharmacokinetics of a new testosterone transdermal delivery system, TDS-testosterone in healthy males.

Authors:  Z Chik; A Johnston; A T Tucker; S L Chew; L Michaels; C A S Alam
Journal:  Br J Clin Pharmacol       Date:  2006-03       Impact factor: 4.335

7.  Hypogonadism in the aging male diagnosis, potential benefits, and risks of testosterone replacement therapy.

Authors:  Prasanth N Surampudi; Christina Wang; Ronald Swerdloff
Journal:  Int J Endocrinol       Date:  2012-03-14       Impact factor: 3.257

8.  Preparation and the biopharmaceutical evaluation for the metered dose transdermal spray of dexketoprofen.

Authors:  Wangding Lu; Huafei Luo; Zhuangzhi Zhu; Yubo Wu; Jing Luo; Hao Wang
Journal:  J Drug Deliv       Date:  2014-02-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.